Nuklearmedizin 2020; 59(02): 107
DOI: 10.1055/s-0040-1708173
Wissenschaftliche Vorträge
Kognitive Störungen
© Georg Thieme Verlag KG Stuttgart · New York

18 F-PI2620 Tau-PET for Assessment of Heterogeneous Neuropathology in Corticobasal Syndrome

J Sauerbeck
1   LMU München, Klinik und Poliklinik für Nuklearmedizin, München
,
C Palleis
2   LMU München, Neurologische Klinik und Poliklinik, München
,
M Brendel
1   LMU München, Klinik und Poliklinik für Nuklearmedizin, München
,
C Prix
2   LMU München, Neurologische Klinik und Poliklinik, München
,
M Gehmeyr
2   LMU München, Neurologische Klinik und Poliklinik, München
,
K Bötzel
3   LMU München, München
,
A Danek
2   LMU München, Neurologische Klinik und Poliklinik, München
,
L Beyer
1   LMU München, Klinik und Poliklinik für Nuklearmedizin, München
,
M Song
1   LMU München, Klinik und Poliklinik für Nuklearmedizin, München
,
A Stephens
4   Piramal Imaging GmbH, Berlin
,
H Barthel
5   University of Leipzig, Klinik und Poliklinik für Nuklearmedizin, Leipzig
,
O Sabri
6   University of Leipzig, Leipzig
,
A Drzezga
7   University of Cologne, Klinik und Poliklinik für Nuklearmedizin, Köln
,
T van Eimeren
8   University of Cologne, Klinik und Poliklinik für Nuklearmedizin, Köln
,
V Villemagne
9   University of Melbourne, The Florey Institute of Neuroscience and Mental Health, Melbourne
,
P Bartenstein
1   LMU München, Klinik und Poliklinik für Nuklearmedizin, München
,
R Perneczky
10   LMU München, Klinik für Psychiatrie und Psychotherapie, München
,
C Haass
11   DZNE, München
,
J Levin
2   LMU München, Neurologische Klinik und Poliklinik, München
,
G Höglinger
11   DZNE, München
› Author Affiliations
Further Information

Publication History

Publication Date:
08 April 2020 (online)

Also available at
 

Ziel/Aim The phenotype of corticobasal syndrome (CBS) is characterized by 4-repeat (4R)-tau in ~50 % and by (3/4R)-tau in ~25 % of histopathologically evaluated patients. The next generation tau-PET ligand 18F-PI2620 showed high affinity to 3/4R tau in Alzheimer’s disease (AD) and also revealed affinity to 4R-tau pathology. The aim of this study was to investigate 18F-PI2620 in patients with clinical CBS.

Methodik/Methods Twenty-two patients (69±8y) with probable or possible CBS according to MDS-PSP or Armstrong-criteria underwent 18F-PI2620 PET together with ten age-matched healthy-controls. Distribution volume ratios (DVR, 0-60min) of subcortical and cortical brain-regions were generated using cerebellar reference tissue. DVR-data were quantitatively and visually compared between CBS and healthy-controls. Regional 18F-PI2620 binding was compared with clinical severity (PSPRS), and disease duration. Amyloid-PET served for assessment of β-amyloid status.

Ergebnisse/Results 23 % (5/22) of CBS patients (PSPRS: 24±14) were amyloid-positive. Significantly elevated 18F-PI2620 DVR was observed in the whole group of CBS patients versus healthy controls in the putamen, globus pallidus and subthalamic nucleus while a trend was observed in frontal cortex. Overall, a visually discernible 18F-PI2620 was observed in 14 subjects (64 %) of the total cohort [9/17 (53 %) of the amyloid negative, 5/5 (100 %) of amyloid-positive CBS patients]. Cortical binding in CBS was heterogeneous with involvement of motor and/or parieto-temporal regions (positive in 41 %; 9/22). 18F-PI2620 binding was not associated with disease severity but showed a correlation with disease duration in frontal cortex (R=0.48, p=0.039).

Schlussfolgerungen/Conclusions Our data indicate a value of 18F-PI2620 for evaluation of CBS, facilitating detection of heterogeneous neuropathology and variable cortical and subcortical deposition sites, which could serve for target engagement.